Monday, 25 February 2019

AstraZeneca's Lynparza meets main goal of late-stage cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for pancreatic cancer.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)